The short version of modified GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
=== Polymers === Already the first work on vinylene carbonate describes its bulk polymerization a colorless polymer, which hydrolyzes to a water-soluble product. Subsequent publications suggest that the first authors produced only low molecular weight oligomers. The preparation of higher molecular weight polymers with useful properties depends critically on the purity of the vinylene carbonate monomer. Vinylene carbonate can be homopolymerized in bulk, in solution, in suspension and in dispersion using radical initiators such as azobis(isobutyronitrile) (AIBN) or benzoyl peroxide. It can also be copolymerized with other vinyl monomers such as vinyl pyrrolidone or vinyl propionate.
Smith Eugene Kashper (1992), owner of Pabst Brewing Company Rob Speyer (1992), president of Tishman Speyer, son of billionaire Jerry Speyer '62 Thad Sheely (1993), former COO of Atlanta Hawks Shawn Landres (1994), social entrepreneur, co-founder of Jewish philanthropic organization Jumpstart Welly Yang (1994), real estate developer; former actor and playwright Ann Kim (1995), James Beard Foundation Award-winning restaurateur in Minneapolis Matt Pincus (1995), founder of Songs Music Publishing, son of Warburg Pincus co-founder Lionel Pincus Arnold Kim (1996), founder of MacRumors Daniel M. Ziff (1996), third youngest billionaire hedge fund manager in the U.S., son of publishing magnate William Bernard Ziff Jr. Li Lu (1996), former student leader of the Tiananmen Square protests of 1989, investment banker, founder of Himalaya Capital Michelle Patron (1996), director of sustainability at Microsoft Scott Sartiano (1997), restaurateur Roo Rogers (1998), entrepreneur, business designer, writer, son of British architect Richard Rogers Amol Sarva (1998), founder of Knotel, Peek, and Virgin Mobile USA Amanda Steinberg (1999), wealth advisor and founder of DailyWorth Shazi Visram (1999), founder of Happy Family Peter Kujawski (2000), chairman of Focus Features Robert Reffkin (2000), co-founder and CEO of Compass, Inc.
Caldwell Dyson is a private pilot. She is conversational in American Sign Language and Russian. She is also the lead vocalist for the all-astronaut band Max Q. In 2011, Caldwell Dyson served as the guest judge on a space-themed episode of the Food Network show Cupcake Wars. She appeared on Episode 3 of MasterChef Junior Season 4. Caldwell Dyson advised Jessica Chastain when the actress was preparing to appear as an astronaut and mission commander in the 2015 movie The Martian. Chastain said she was very inspired by Caldwell Dyson. Caldwell Dyson is a member of Sigma Xi Research Society and the American Chemical Society.
== Plot == While working with a team from the University of Chicago on a project to convert hydrogen from water into clean energy, student machinist Eddie Kasalivich inadvertently discovers a sound frequency in his home laboratory that perfectly stabilizes their process the next day. As the team celebrates with a party at the project laboratory, Dr. Paul Shannon, the leader of the project, and Dr. Alistair Barkley, the project manager, debate whether or not to share the scientific discovery. Later that night, project physicist Dr. Lily Sinclair finds her car unable to start, so Eddie gets her home by bus. Back in the laboratory, Alistair and assistant Dr. Lu Chen prepare to upload their discovery to the Internet to share the breakthrough with the world, while a van approaches the premises. Chen hears a noise and goes outside to investigate, but is kidnapped by unknown assailants as Alistair is also attacked. Once he has dropped Lily off at Alistair's house, where she lives on the third floor, Eddie returns to the laboratory to retrieve his motorcycle but notices a suspicious van departing. Hearing alarms, he runs inside to find Alistair dead with a plastic bag over his head and Chen missing. As the hydrogen reactor has become dangerously unstable, Eddie, unable to deactivate it, speeds away as a concealed detonator triggers a massive hydrogen explosion that destroys the laboratory and eight blocks' worth of surrounding streets.
Sources: en.wikipedia.org
=== Home goods === Diatomaceous earth (DE) is used in some home products where dryness or the ability to wick away moisture is needed. In particular there are bath mats made of DE which absorb water from the bather and allow it to spread the material and rapidly evaporate. There are also spoons made of DE for scooping sugar and other hygroscopic kitchen ingredients.
=== Signal transduction === The effects of insulin are initiated by its binding to a receptor, the insulin receptor (IR), present in the cell membrane. The receptor molecule contains an α- and β subunits. Two molecules are joined to form what is known as a homodimer. Insulin binds to the α-subunits of the homodimer, which faces the extracellular side of the cells. The β subunits have tyrosine kinase enzyme activity which is triggered by the insulin binding. This activity provokes the autophosphorylation of the β subunits and subsequently the phosphorylation of proteins inside the cell known as insulin receptor substrates (IRS). The phosphorylation of the IRS activates a signal transduction cascade that leads to the activation of other kinases as well as transcription factors that mediate the intracellular effects of insulin. The cascade that leads to the insertion of GLUT4 glucose transporters into the cell membranes of muscle and fat cells, and to the synthesis of glycogen in liver and muscle tissue, as well as the conversion of glucose into triglycerides in liver, adipose, and lactating mammary gland tissue, operates via the activation, by IRS-1, of phosphoinositol 3 kinase (PI3K). This enzyme converts a phospholipid in the cell membrane by the name of phosphatidylinositol 4,5-bisphosphate (PIP2), into phosphatidylinositol 3,4,5-triphosphate (PIP3), which, in turn, activates protein kinase B (PKB). Activated PKB facilitates the fusion of GLUT4 containing endosomes with the cell membrane, resulting in an increase in GLUT4 transporters in the plasma membrane.
Libiguin A is a naturally occurring limonoid found in Neobeguea mahafalensis, a flowering plant found in Madagascar with a long history of traditional medical use. It is a derivative of phragmalin. The compound has been reported to produce highly potent, strong, and long-lasting pro-sexual effects in rodents. The semisynthesis of libiguin A from phragmalin has been described. An analogue also found in Neobeguea mahafalensis, libiguin B, has similar pro-sexual effects but is far less potent in comparison. Another analogue, a synthetic compound known as volufralin (LIB-01; DIC-2024), is under development for the treatment of erectile dysfunction and premature ejaculation. Libiguin A was first described in the scientific literature by 2014.
P7C3 (pool 7, compound 3) is a drug related to latrepirdine (dimebon) which has neuroprotective and proneurogenic effects and may be potentially useful for the treatment of Alzheimer's disease and similar neurodegenerative disorders. The pharmacological effects of P7C3 in vitro resemble those of endogenous proneurogenic peptides such as fibroblast growth factor 1 (FGF-1), and the proneurogenic activity of P7C3 was around thirty times that of latrepirdine when they were compared in mice. P7C3 was chosen for further animal studies on the basis of favorable pharmacokinetic factors, such as its high oral bioavailability and long duration of action, but several other related compounds showed similar activity such as the more potent fluorinated analogue P7C3-A20 which is up to ten times stronger again, and the methoxy analogue P7C3-OMe, for which it was determined that the (R) enantiomer is the active form.
The term thagomizer was coined by Gary Larson in jest. In a 1982 The Far Side comic, a group of cavemen are taught by a caveman lecturer that the spikes on a stegosaur's tail were named "after the late Thag Simmons". The term was picked up initially by Kenneth Carpenter, then a paleontologist at the Denver Museum of Nature and Science, who used the term when describing a fossil at the Society of Vertebrate Paleontology Annual Meeting in 1993. Thagomizer has since been adopted as an anatomical term and is used by the Smithsonian Institution, the Dinosaur National Monument, the book The Complete Dinosaur and the BBC documentary series Planet Dinosaur. The term has also appeared in some scientific papers describing stegosaurs and related dinosaurs.
Sources: en.wikipedia.org
== Incorporating solvent effects == In many simulations of a solute-solvent system the main focus is on the behavior of the solute with little interest of the solvent behavior particularly in those solvent molecules residing in regions far from the solute molecule. Solvents may influence the dynamic behavior of solutes via random collisions and by imposing a frictional drag on the motion of the solute through the solvent. The use of non-rectangular periodic boundary conditions, stochastic boundaries and solvent shells can all help reduce the number of solvent molecules required and enable a larger proportion of the computing time to be spent instead on simulating the solute. It is also possible to incorporate the effects of a solvent without needing any explicit solvent molecules present. One example of this approach is to use a potential mean force (PMF) which describes how the free energy changes as a particular coordinate is varied. The free energy change described by PMF contains the averaged effects of the solvent. Without incorporating the effects of solvent simulations of macromolecules (such as proteins) may yield unrealistic behavior and even small molecules may adopt more compact conformations due to favourable van der Waals forces and electrostatic interactions which would be dampened in the presence of a solvent.
== Phosphoanhydride bond formation == While early studies of phosphorimidazolide derivatives of nucleotides found that oligonucleotides could form in the presence of a complementary template, pyrophosphate-linked dimers formed predominantly in the absence of a template. This proclivity for forming new phosphoanhydride bonds has been used in the synthesis of several pyrophosphate-containing organic compounds. A variety of modified nucleotide triphosphates were synthesized using a cyanoethyl-protected phosphorimidazolide reagent. Phosphoanhydride bond forming reactions were found to proceed most rapidly in amide-based organic solvents such as N,N-dimethylformamide and particularly in N,N-dimethylacetamide with Mg2+ or Zn2+ catalysts.
== Prognosis == The prognosis of primary Raynaud syndrome is often excellent, with no factor to mortality and little morbidity overall. In some very rare cases, gangrene has been known to develop. The prognosis of secondary Raynaud is related to the course of the underlying disease, and how effective blood flow-restoring maneuvers are.
Despite this, the use of urine myoglobin measurement is not supported by evidence as it lacks specificity and the research studying its utility is of poor quality. Elevated concentrations of the enzyme lactate dehydrogenase (LDH) may be detected. Other markers of muscle damage, such as aldolase, troponin, carbonic anhydrase type 3 and fatty acid-binding protein (FABP), are mainly used in chronic muscle diseases. The transaminases, enzymes abundant in both liver and muscle tissue, are also usually increased; this can lead to the condition being confused with acute liver injury, at least in the early stages. The incidence of actual acute liver injury is 25% in people with non-traumatic rhabdomyolysis; the mechanism for this is uncertain. High potassium levels tend to be a feature of severe rhabdomyolysis. Electrocardiography (ECG) may show whether the elevated potassium levels are affecting the conduction system of the heart, as suggested by the presence of T wave changes or broadening of the QRS complex. Low calcium levels may be present in the initial stage due to binding of free calcium to damaged muscle cells. As detectable levels of myoglobinemia and myoglobinuria occur, blood tests and urine tests may show elevated levels of myoglobin. For example, a urine test strip may reveal a positive result for "blood", even though no red blood cells can be identified on microscopy of the urine; this occurs because the reagent on the test strip reacts with myoglobin.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.